Clinical applicability of diagnostic biomarkers in early-onset cognitive impairment

European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies
N FalgàsAlbert Lladó

Abstract

Several diagnostic biomarkers are currently available for clinical use in early-onset cognitive impairment. The decision on which biomarker is used in each patient depends on several factors such as its predictive value or tolerability. There were a total of 40 subjects with early-onset cognitive complaints (<65 years of age): 26 with Alzheimer's disease (AD), five with frontotemporal dementia and nine with diagnostic suspicion of non-neurodegenerative disorder. Clinical and neuropsychological evaluation, lumbar puncture for cerebrospinal fluid (CSF) AD core biochemical marker determination, medial temporal atrophy evaluation on magnetic resonance imaging, amyloid-positron emission tomography (PET) and 18 F-fluorodeoxyglucose-PET were performed. Neurologists provided pre- and post-biomarker diagnosis, together with diagnostic confidence and clinical/therapeutic management. Patients scored the tolerability of each procedure. Cerebrospinal fluid biomarkers and amyloid-PET increased diagnostic confidence in AD (77.4%-86.2% after CSF, 92.4% after amyloid-PET, P < 0.01) and non-neurodegenerative conditions (53.6%-75% after CSF, 95% after amyloid-PET, P < 0.05). Biomarker results led to diagnostic (32.5%) and treatment (32.5%) change...Continue Reading

References

Apr 6, 2007·International Journal of Psychiatry in Medicine·Mario F Mendez
Feb 18, 2011·Neurology·M L Gorno-TempiniM Grossman
May 18, 2011·Neurology·M BalasaUNKNOWN Neurological Tissue Bank/University of Barcelona/Hospital Clínic NTB/UB/HC Collaborative Group
Aug 4, 2011·Brain : a Journal of Neurology·Katya RascovskyBruce L Miller
Jul 31, 2013·Neurology·Giovanni B FrisoniUNKNOWN ISTAART's NeuroImaging Professional Interest Area
Mar 1, 2014·Journal of Alzheimer's Disease : JAD·Mircea BalasaAlbert Lladó
Aug 27, 2014·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Flora H DuitsWiesje M van der Flier
Oct 22, 2016·Journal of Alzheimer's Disease : JAD·Philip S J WestonJonathan M Schott
Feb 28, 2017·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Arno de WildeWiesje M van der Flier
Jul 20, 2017·Lancet Neurology·Giovanni B FrisoniBengt Winblad
Oct 27, 2017·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Marleen KunnemanEllen M A Smets

❮ Previous
Next ❯

Citations

Jul 4, 2019·Journal of Neurology·Daniele AltomareUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Jan 21, 2020·Journal of Alzheimer's Disease : JAD·Neus FalgàsAlbert Lladó
Aug 18, 2020·Neuropsychiatric Disease and Treatment·Koung Mi KangUNKNOWN KBASE Research Group
Sep 10, 2019·Frontiers in Neuroscience·Nick BergauAlexander Navarrete Santos
Feb 4, 2021·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Mélanie BrissonJean-Paul Soucy
Sep 3, 2021·NeuroImage. Clinical·José ContadorUNKNOWN Alzheimer's Disease Neuroimaging Initiative

❮ Previous
Next ❯

Related Concepts

Related Feeds

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.